July 25, 2026 a 04:38 pm
AMGN: Analysts Ratings - Amgen Inc.
Amgen Inc. has maintained a strong foothold in the biotechnology sector, leveraging its diverse product portfolio and strategic collaborations. The recent analytical data indicates a steady sentiment among analysts, with a notable inclination towards "Hold" recommendations. This reflects a period of cautious market optimism, balancing the risks associated with sector volatility and potential growth through innovation and partnerships.
Historical Stock Grades
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 4 | |
| Buy | 10 | |
| Hold | 17 | |
| Sell | 2 | |
| Strong Sell | 1 |
Sentiment Development
The data reveals a gradual increase in "Hold" recommendations, indicating a shift towards a more neutral sentiment over recent months. This trend suggests a market cautiousness, likely triggered by external factors influencing the biotech sector. Despite fluctuations, the "Buy" category has remained relatively stable, maintaining investor confidence in Amgen's robust pipeline and strategic initiatives.
- "Hold" ratings have seen a gradual increase, peaking recently.
- Strong Buy recommendations decreased from early 2025 levels.
- The total number of ratings has shown stability over the months, implying consistent analyst engagement.
Percentage Trends
A detailed percentage analysis showcases a shift in sentiment distribution, with a notable rise in "Hold" ratings at the expense of lesser "Strong Buy" recommendations. This may reflect the evolving market conditions and investor skepticism over extended growth prospects amidst industry challenges.
- July 2025 saw the highest percentage of "Strong Buy" ratings (20%).
- Recent months indicate a significant uptick in "Hold" recommendations, comprising nearly 50% of all ratings in July 2026.
- The decrease in "Strong Buy" and "Buy" ratings emphasize a trend towards more neutrality and caution.
Latest Analyst Recommendations
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-07-13 | Neutral | Neutral | Guggenheim |
| 2026-07-13 | Buy | Buy | UBS |
| 2026-07-08 | Equal Weight | Equal Weight | Morgan Stanley |
| 2026-07-07 | Hold | Hold | Truist Securities |
| 2026-07-06 | Neutral | Neutral | Cantor Fitzgerald |
Analyst Recommendations with Change of Opinion
The latest changes reveal a conservative tilt, with multiple downgrades pointing towards a more tempered outlook. These shifts underscore the cautious stance analysts are adopting amid unpredictable market dynamics and sector-specific factors affecting biotech stocks.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-02-12 | Hold | Buy | Freedom Broker |
| 2026-01-20 | Market Perform | Outperform | Bernstein |
| 2024-10-14 | Hold | Buy | Truist Securities |
| 2024-08-07 | Equal Weight | Overweight | Wells Fargo |
| 2024-05-03 | Outperform | Market Perform | William Blair |
Interpretation
The prevailing market sentiment towards Amgen Inc. suggests a cautious optimism. Analyst recommendations highlight a stability in their evaluations but reflect an overall conservative outlook with a trend towards neutral positioning. This suggests a recognition of potential risks balanced by Amgen's strong market position and the dynamism of its product offerings and partnerships. The steady "Hold" percentage indicates relative trust but also reflects reservations regarding near-term market variables.
Conclusion
In conclusion, Amgen Inc. continues to exhibit resilience in the biotechnology sector, backed by a diverse pipeline and strategic collaborations. While analyst sentiment demonstrates a more cautious approach, potentially due to industry-wide uncertainties, the fundamental strength and innovation potential of Amgen provide a positive long-term outlook. Investors may want to weigh current market volatility against the horizon of potential growth opportunities and ongoing sector advancements.
Smart Data Insight
Master the Perfect Entry & Exit for this Stock
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.
- ✅ Identify the "Golden Buying Window"
- ✅ Avoid high-risk correction cycles
- ✅ Backtested data from the last 20+ years